PMID- 15129427
OWN - NLM
STAT- MEDLINE
DCOM- 20040615
LR  - 20211203
IS  - 0270-4137 (Print)
IS  - 0270-4137 (Linking)
VI  - 60
IP  - 1
DP  - 2004 Jun 15
TI  - Immunological monitoring during combination of patient-oriented peptide 
      vaccination and estramustine phosphate in patients with metastatic hormone 
      refractory prostate cancer.
PG  - 32-45
AB  - BACKGROUND: Additive antitumor effects could be achieved by combination of 
      immunotherapy and cytotoxic agents with no or minimum suppression. METHODS: 
      Thirteen patients positive for human leukocyte antigen (HLA)-A24 or -A2 with 
      metastatic hormone refractory prostate cancer (HRPC) who had failed to respond to 
      the prior-peptide vaccination were entered in the combined peptide vaccination 
      and estramustine phosphate. Conducted immune monitoring on those 13 patients were 
      mainly peptide-specific cytotoxic T lymphocyte (CTL) precursor analysis by 
      IFN-gamma productions and peptide-reactive IgG by an enzyme-linked immunosorbent 
      assay (ELISA). RESULTS: Grade 3 arrhythmia or cerebral infarction was observed in 
      two cases, and Grade 1 or 2 dermatologic reaction at the vaccination sites was 
      observed in all 13 cases. Eleven patients who received more than one cycle of 
      treatment were eligible for immunological and clinical evaluation. There was no 
      significant immunosuppression in most cases when the peptide and a half dose (280 
      mg/day) of estramustine were administrated, whereas severe immunosuppression was 
      observed in the first two patients who received both the peptide and a full dose 
      (560 mg/day) estramustine. Augmentation of peptide-specific CTL precursors or 
      peptide-specific IgG was observed in 6 of 11 or 10 of 11 cases, respectively. Ten 
      of 11 patients showed serum prostate-specific antigen (PSA) level decrease from 
      the baseline including 8 patients with a serum PSA level decrease of > or =50%. 
      CONCLUSIONS: These results encouraged the further evaluation of the combination 
      of peptide vaccination and low-dose estramustine phosphate for metastatic HRPC 
      patients.
CI  - Copyright 2004 Wiley-Liss, Inc.
FAU - Noguchi, Masanori
AU  - Noguchi M
AD  - Department of Urology, Kurume University School of Medicine, Asahi-machi, Kurume, 
      Japan. noguchi@med.kurume-u.ac.jp
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Suekane, Shigetaka
AU  - Suekane S
FAU - Morinaga, Akiko
AU  - Morinaga A
FAU - Sukehiro, Aki
AU  - Sukehiro A
FAU - Suetsugu, Norie
AU  - Suetsugu N
FAU - Katagiri, Kazuko
AU  - Katagiri K
FAU - Yamada, Akira
AU  - Yamada A
FAU - Noda, Shinshi
AU  - Noda S
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Journal Article
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Vaccines, Subunit)
RN  - 35LT29625A (Estramustine)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Antineoplastic Agents, Hormonal/*therapeutic use
MH  - Combined Modality Therapy
MH  - Drug Resistance, Neoplasm
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Estramustine/administration & dosage/*therapeutic use
MH  - Humans
MH  - Immunoglobulin G/analysis
MH  - Immunosuppression Therapy
MH  - Interferon-gamma/analysis/biosynthesis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Prostate-Specific Antigen/analysis
MH  - Prostatic Neoplasms/*drug therapy/*immunology
MH  - Vaccines, Subunit/*administration & dosage/*immunology
EDAT- 2004/05/07 05:00
MHDA- 2004/06/16 05:00
CRDT- 2004/05/07 05:00
PHST- 2004/05/07 05:00 [pubmed]
PHST- 2004/06/16 05:00 [medline]
PHST- 2004/05/07 05:00 [entrez]
AID - 10.1002/pros.20011 [doi]
PST - ppublish
SO  - Prostate. 2004 Jun 15;60(1):32-45. doi: 10.1002/pros.20011.